KBY Biotech Indexv0.0.34
Search
← Pipeline|RHH-7558

RHH-7558

Phase 1
By Roche
Source: Trial-derived·Trials: 1
Modality
ADC
MOA
Anti-Tau
Target
SGLT2
Pathway
Neuroinflam
Fabry
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
May 2019
Phase 1Current
NCT03549234
2,283 pts·Fabry
2019-05→TBD·Completed
2,283 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1
Complet…
Completed|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03549234Phase 1FabryCompleted2283BodyWt
Competitors (10)
DrugCompanyPhaseTargetMOA
TiramavacamtenRochePreclinicalSGLT2PI3Ki
NVS-5439NovartisPreclinicalBETAnti-Tau
NVO-9630Novo NordiskPhase 2CD3Anti-Tau
RimatenlimabNovo NordiskPhase 2/3SGLT2PI3Ki
DSN-7360Daiichi SankyoApprovedSGLT2BiTE
REG-2172RegeneronPhase 1/2PCSK9Anti-Tau
BGN-3305BeiGenePhase 2BCMAAnti-Tau
SRP-3270SareptaPhase 1/2SGLT2PI3Ki
TirarapivirUnited TherapeuticsApprovedSGLT2CD47i
SovarasimodHalozymePhase 1/2WEE1Anti-Tau